Tag: 170161-27-0

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: A solution of x,y-bis(bromomethyl)-1,1′-biphenyl (x,y = 3,3? or 4,4?) (3,3′-bis(bromomethyl)-1,1′-biphenyl/ 4,4′-bis(bromomethyl)-1,1′-biphenyl)S2 (68.0 mg, 200 mumol) was added to a solution of tri-tert-butyl1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (25.0 mg, 500 mumol), K2CO3 (6.90 mg, 500 mumol)in CH3CN (1.50 mL) under N2 and stirred for 12 hr at room temperature. The reaction mixture wasconcentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with waterand brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protectedamine intermediates. A solution of the intermediates was added to bis(pyridin-2-ylmethyl)amine (15.3 mg,77.0 mumol), KI (2.50 mg, 15.0 mumol) and K2CO3 (2.10 mg, 15.0 mumol) in CH3CN (5.00 mL) under N2 andstirred at 80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted withEtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuoto obtain the corresponding tri-N-Boc-protected amine intermediates. The intermediates were thendissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixturewas concentrated under reduced pressure and purified by preparative HPLC to obtain the desiredcompounds 4-5.

170161-27-0, 170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: A solution of x,y-bis(bromomethylnaphthalene) (x,y = 2,7, 2,6 or 1,6) (2,7-bis(bromomethyl)naphthalene;126 mg, 400 mumol / 2,6-bis(bromomethyl)naphthalene; 72.0 mg, 100 mumol / 1,6-bis(bromomethyl)naphthalene; 31.4 mg, 100 mumol)S1 was added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (50.1 mg, 100 mumol), KI (16.6 mg, 100 mumol) and K2CO3(10.8 mg, 78.0 mumol) in CH3CN (3.50 mL) under N2 and stirred for 24 h at room temperature. The reactionmixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washedwith water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Bocprotectedamine intermediates. A solution of the intermediates was added to bis(pyridin-2-ylmethyl)amine(Dpa) (12.0 mg, 60.0 mumol) and K2CO3 (8.30 mg, 60.0 mumol) in CH3CN (3.00 mL) under N2 and stirred at80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc.The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtainthe corresponding tri-N-Boc-protected amine intermediates. The intermediates were then dissolved inCHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6.0 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 1-3.

170161-27-0, As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

a 1-[4-(bromomethyl)phenylmethyl]-4,8,11-tri-(t-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecane alpha,alpha’-Dibromo-p-xylene (36.0 g, 136 mmol) was stirred at 60 C. in acetonitrile (500 mL) until it dissolved. Potassium carbonate (3.5 g, 25.3 mmol) was added, followed by the dropwise addition of a solution of 1,4,8-tri-(t-butyloxycarbonyl)-1,4,8,11-tetraazacyclotetradecane (Boitrel, et. al., Tetrahedron Lett., 1995, 36, 4995) (6.0 g, 11.98 mmol) in acetonitrile (100 mL). The mixture was stirred for 6 hours, cooled and partially evaporated. The excess dibromoxylene was filtered off, the mother liquors evaporated under vacuum and chromatographed (silica gel, 50% dichloromethane/hexane to 2% methanol/dichloromethane) to afford the title compound as a foam (7.4 g, 90%). MS (ES+) m/e 683 and 685 [M+H]+

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SmithKline Beecham Corporation; US2002/107195; (2002); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

A mixture of 4-ethynylbenzaldehyde (65 mg, 500 mol) and triBoc-cyclam (250 mg, 500mol) in dichloromethane (4 mL) was stirred at ambient temperature for 2 h, and then sodiumtriacetoxyborohydride (318 mg, 1.5 mmol) was added. The mixture was stirred at ambient temperatureovernight. The reaction was quenched with aqueous NaHCO3, the layers were separated and theaqueous layer was extracted with dichloromethane. The combined organic layers were dried overanhydrous sodium sulfate and evaporated, and the crude residue was purified by Combi-Flash (silica gel;ethyl acetate in hexanes) to give p-RPS-546 (185 mg 60%) as a white solid.

170161-27-0, 170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Amor-Coarasa, Alejandro; Kelly, James M.; Singh, Pradeep K.; Ponnala, Shashikanth; Nikolopoulou, Anastasia; Williams, Clarence; Vedvyas, Yogindra; Jin, Moonsoo M.; David Warren; Babich, John W.; Molecules; vol. 24; 8; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The dibromide was added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (39.1 mg, 78.0 mumol), KI (12.9 mg, 78.0 mumol) and K2CO3 (10.8 mg, 78.0 mumol) in CH3CN (2.50 mL) under N2 and stirred for 24 h at room temperature. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediate (130 mg). A solution of the intermediate was added to bis(pyridin-2-ylmethyl)amine (12.0 mg, 60.0 mumol), KI (9.96 mg, 60.0 mumol) and K2CO3 (8.30 mg, 60.0 mumol) in CH3CN (3.00 mL) under N2 and stirred at 80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediate. The intermediate was then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compound 16.

170161-27-0, As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The y-carbaldehyde intermediates (y = 3 or 4) (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (30.0 mg, 60.0 mumol) in MeOH (1.00 mL) andAcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (7.50 mg, 120 mumol) wasadded to the reaction mixture slowly and stirred at room temperature for 20 h. The reaction mixture waspoured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was thenwashed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain thecorresponding tri-N-Boc-protected amine intermediates. The intermediates were then dissolved in CHCl3(2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentratedunder reduced pressure and purified by preparative HPLC to obtain the desired compounds 19-22.

The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: A solution of x,y-bis(bromomethylnaphthalene) (x,y = 2,7, 2,6 or 1,6) (2,7-bis(bromomethyl)naphthalene;126 mg, 400 mumol / 2,6-bis(bromomethyl)naphthalene; 72.0 mg, 100 mumol / 1,6-bis(bromomethyl)naphthalene; 31.4 mg, 100 mumol)S1 was added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (50.1 mg, 100 mumol), KI (16.6 mg, 100 mumol) and K2CO3(10.8 mg, 78.0 mumol) in CH3CN (3.50 mL) under N2 and stirred for 24 h at room temperature. The reactionmixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washedwith water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Bocprotectedamine intermediates. A solution of the intermediates was added to bis(pyridin-2-ylmethyl)amine(Dpa) (12.0 mg, 60.0 mumol) and K2CO3 (8.30 mg, 60.0 mumol) in CH3CN (3.00 mL) under N2 and stirred at80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc.The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtainthe corresponding tri-N-Boc-protected amine intermediates. The intermediates were then dissolved inCHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6.0 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 1-3.

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The y-carbaldehyde intermediates (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (35.7 mg, 71.0 mumol) in MeOH (1.0 mL) and AcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (8.90 mg, 142 mumol) was added slowly to the reaction mixture and stirred at room temperature for 24 h. The reaction mixture was poured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was then washed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain the corresponding tri-N-Boc-protected amine intermediates (68.9 mg), which were used in the next step without purification. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 6-12.

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

[00132] To a solution of 1 -pyrenecarboxaldehyde (35 mg, 0.15 mmol) in 1 ml_ DCE, Boc3Cyclam (50 mg, 0.10 mmol) was added and stirred together with 4A molecular sieves for 2 h under nitrogen atmosphere. To this solution sodium triacetoxyborohydride (42 mg, 0.2 mmol) was added and the reaction mixture was allowed to stir at ambient temperature over 24 h under nitrogen atmosphere. Subsequently, the reaction mixture was diluted with sodium bicarbonate and extracted with DCM. The extract was purified by flash chromatography with 30% ethyl acetate/hexanes to give the product (63 mg, 88%); 1H NMR (400 MHz, CDC) delta 8.47 (d, J = 9.3 Hz, 1H), 8.21 – 7.93 (m, 8H), 4.22 (s, 2H), 3.34 (s, 10H), 3.13 (s, 2H), 2.78 (s, 2H), 2.50 (s, 2H), 1.88 (s, 2H), 1.76 – 1.66 (m, 2H), 1.51 – 1.17 (m, 27H); 13C NMR (100 MHz, CDCb) delta 155.55, 132.64, 131.33, 130.87, 130.77, 129.71, 128.41, 127.47, 127.10, 125.83, 125.00, 124.83, 124.50, 124.06, 79.67, 79.44, 58.59, 54.24, 53.43, 47.81, 47.07, 29.72, 28.50, 28.46, 28.31 ; LRMS (ESI+) m/z calc’d for CHssN-OeNa [M + Na]+ 737.42, found 737.65.

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO; GUNNING, Patrick Thomas; KRASKOUSKAYA, Dziyana; CABRAL, Aaron; MURCAR-EVANS, Bronte; TOUTAH, Krimo; DE ARAUJO, Elvin; (141 pag.)WO2019/68177; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: The y-carbaldehyde intermediates (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (35.7 mg, 71.0 mumol) in MeOH (1.0 mL) and AcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (8.90 mg, 142 mumol) was added slowly to the reaction mixture and stirred at room temperature for 24 h. The reaction mixture was poured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was then washed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain the corresponding tri-N-Boc-protected amine intermediates (68.9 mg), which were used in the next step without purification. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 6-12.

The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI